JAKs are involved in different inflammatory and autoimmune diseases, and tofacitinib and baricitinib are selective JAK inhibitors that preferentially inhibit JAK1 and JAK3 and JAK1 and JAK2, respectively. This evidence concerns the gene JAK1 and autoimmune disease.